BE2019C544I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C544I2
BE2019C544I2 BE2019C544C BE2019C544C BE2019C544I2 BE 2019C544 I2 BE2019C544 I2 BE 2019C544I2 BE 2019C544 C BE2019C544 C BE 2019C544C BE 2019C544 C BE2019C544 C BE 2019C544C BE 2019C544 I2 BE2019C544 I2 BE 2019C544I2
Authority
BE
Belgium
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Application number
BE2019C544C
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C544(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BE2019C544I2 publication Critical patent/BE2019C544I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2019C544C 2001-07-31 2019-10-23 BE2019C544I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr) 2001-07-31 2002-07-30 Methodes de mobilisation de cellules souches/embryonnaires
EP02750370A EP1411918B1 (fr) 2001-07-31 2002-07-30 Methodes de mobilisation de cellules souches/embryonnaires

Publications (1)

Publication Number Publication Date
BE2019C544I2 true BE2019C544I2 (fr) 2021-07-19

Family

ID=26976666

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C544C BE2019C544I2 (fr) 2001-07-31 2019-10-23

Country Status (29)

Country Link
US (9) US6987102B2 (fr)
EP (3) EP3632425A1 (fr)
JP (2) JP5137288B2 (fr)
KR (2) KR100996378B1 (fr)
CN (2) CN102302493B (fr)
AT (1) ATE538785T1 (fr)
AU (1) AU2002318927B2 (fr)
BE (1) BE2019C544I2 (fr)
BR (1) BRPI0211570B8 (fr)
CA (1) CA2455559C (fr)
CY (4) CY1112633T1 (fr)
DK (2) DK1411918T3 (fr)
ES (2) ES2742730T3 (fr)
FR (2) FR12C0042I1 (fr)
HK (1) HK1063005A1 (fr)
HU (1) HUP0402360A2 (fr)
IL (2) IL159312A0 (fr)
LT (2) LT2371361T (fr)
LU (2) LU92033I2 (fr)
MX (1) MXPA04000982A (fr)
NL (2) NL300537I2 (fr)
NO (4) NO336989B1 (fr)
NZ (1) NZ530169A (fr)
PL (1) PL364673A1 (fr)
PT (2) PT1411918E (fr)
RU (1) RU2309741C2 (fr)
SI (2) SI2371361T1 (fr)
WO (1) WO2003011277A2 (fr)
ZA (1) ZA200400658B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (da) 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US20050153941A1 (en) * 2003-06-27 2005-07-14 Tomoyuki Miyabayashi Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line
WO2005002522A2 (fr) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions et methodes pour traiter une ischemie tissulaire
US20050069553A1 (en) 2003-08-13 2005-03-31 Yi Zheng Chimeric peptides for the regulation of GTPases
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
EP1796716A4 (fr) * 2004-08-13 2010-09-08 Anormed Inc Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
JP2008519052A (ja) 2004-11-05 2008-06-05 ザ ジェネラル ホスピタル コーポレイション 薬剤によるヒト遊走性細胞の合目的的挙動
EA014644B1 (ru) 2005-06-13 2010-12-30 Кливлэнд Биолабс Инк. Способы защиты от апоптоза с применением липопептидов
AU2006280945A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
EP1924606A4 (fr) * 2005-08-25 2010-01-13 Repair Technologies Inc Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
CN101389329A (zh) * 2006-02-24 2009-03-18 健赞股份有限公司 增加血流和/或促进组织再生的方法
WO2007108689A2 (fr) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2011053700A1 (fr) 2009-10-28 2011-05-05 Henry Ford Health System Méthodes d'atténuation des lésions causées par une irradiation
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
EP3578205A1 (fr) 2010-08-06 2019-12-11 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
CN103596935A (zh) 2011-05-16 2014-02-19 建新公司 Cxcr4拮抗剂的用途
US20160030522A1 (en) * 2013-03-15 2016-02-04 Leonard B. Miller Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
WO2017049208A1 (fr) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Apport localisé d'un agent antichimiorépulsion pour le traitement du cancer
EP3389634B1 (fr) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389720A1 (fr) 2015-12-18 2018-10-24 The General Hospital Corporation Polymères polyacétal, conjugués, particules et utilisations associées
CN108883091A (zh) 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
CA3019394A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
WO2017216373A1 (fr) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
EP3808748A1 (fr) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Piperidines substutues comme inhibiteurs de cxcr4
CA3027495A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2018049120A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
WO2018049124A1 (fr) 2016-09-09 2018-03-15 The General Hospital Corporation Protéine de fusion hsp avec un agent anti-chimiorépulsion pour le traitement d'une maladie infectieuse
JP2019534249A (ja) 2016-09-09 2019-11-28 ザ ジェネラル ホスピタル コーポレイション 癌の治療のための抗化学忌避剤とのｈｓｐ融合タンパク質
WO2018106738A1 (fr) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
EP3720494A2 (fr) * 2017-12-06 2020-10-14 Magenta Therapeutics, Inc. Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
CA3086337A1 (fr) * 2017-12-19 2019-06-27 Gpcr Therapeutics, Inc. Inhibiteurs d'heteromeres gpcr et leurs utilisations
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Of Medicine Methods for increasing stem cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) * 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
HUT62905A (en) 1989-10-23 1993-06-28 Salutar Inc Process for producing metql complexes comprising polydentate metal chelate forming compounds
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
CA2148712C (fr) 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripherisation de cellules souches hematopoietiques
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (fr) * 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
EP1068357B2 (fr) * 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Applications therapeutiques et diagnostiques basees sur le role du gene cxcr-4 dans l'oncogenese
WO1999065507A1 (fr) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulation de la fonction plaquettaire
CA2244554A1 (fr) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition d'une greffe par rapport a la maladie d'un hote
EP1117762A4 (fr) * 1998-09-29 2004-02-25 Gamida Cell Ltd Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
DE69929464T2 (de) * 1998-11-17 2006-09-07 Smithkline Beecham Corp. Zyklische polyamine zur behandlung der thrombozytopenie
EP1016413A1 (fr) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
ES2265923T3 (es) * 1999-03-24 2007-03-01 Anormed Inc. Compuestos heterociclicos que se unen a receptores de quimiocinas.
WO2000066112A1 (fr) * 1999-05-03 2000-11-09 Smithkline Beecham Corporation Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
ATE428706T1 (de) 1999-12-17 2009-05-15 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (fr) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
EP1317443B1 (fr) 2000-09-15 2009-01-14 Anormed Inc. Composes heterocycliques se liant avec les recepteurs de chimiokines
AU9156901A (en) 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1752455B1 (fr) 2000-09-15 2010-11-10 Anormed Inc. Composés hétérocycliques qui lient les recepteurs chemokines.
KR100808385B1 (ko) 2000-09-29 2008-03-07 아노르메드 인코포레이티드 Ｎ-1 보호된 ｎ개 환 질소 함유 사이클릭 폴리아민 및 이의 생성물의 제조방법
US6750339B2 (en) 2001-01-23 2004-06-15 The Procter And Gamble Company Primary intermediates for oxidative coloration of hair
DK1411918T3 (da) 2001-07-31 2012-04-23 Genzyme Global S A R L Fremgangsmåder til at mobilisere progenitor/stamceller
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
CA2455559C (fr) 2012-01-10
EP1411918B1 (fr) 2011-12-28
RU2309741C2 (ru) 2007-11-10
JP5137288B2 (ja) 2013-02-06
US20170049747A1 (en) 2017-02-23
FR19C1058I1 (fr) 2019-11-22
US6987102B2 (en) 2006-01-17
CN102302493B (zh) 2015-08-12
LUC00139I2 (fr) 2021-02-10
NL300537I2 (fr) 2017-02-02
BR0211570A (pt) 2004-07-13
LT2371361T (lt) 2019-09-10
NO2016011I1 (no) 2016-06-10
CY1122199T1 (el) 2020-05-29
US20080063624A1 (en) 2008-03-13
FR19C1058I2 (fr) 2020-10-23
ZA200400658B (en) 2005-07-27
US20060193826A1 (en) 2006-08-31
CN102302493A (zh) 2012-01-04
HK1063005A1 (en) 2004-12-10
US7935692B2 (en) 2011-05-03
BRPI0211570B8 (pt) 2021-05-25
NL301031I2 (nl) 2020-07-20
MXPA04000982A (es) 2004-04-20
NO336989B1 (no) 2015-12-14
CY2019038I1 (el) 2020-05-29
LTPA2019018I1 (lt) 2019-12-10
ATE538785T1 (de) 2012-01-15
US20150246019A1 (en) 2015-09-03
PL364673A1 (en) 2004-12-13
KR20090130152A (ko) 2009-12-17
NZ530169A (en) 2007-04-27
CN1561208B (zh) 2010-11-10
ES2742730T3 (es) 2020-02-17
US20190216773A1 (en) 2019-07-18
NO20040407L (no) 2004-03-19
US20060223180A1 (en) 2006-10-05
PT2371361T (pt) 2019-09-10
IL159312A (en) 2015-05-31
ES2380009T3 (es) 2012-05-07
US20030130250A1 (en) 2003-07-10
CN1561208A (zh) 2005-01-05
LUC00139I1 (fr) 2019-11-27
EP3632425A1 (fr) 2020-04-08
EP1411918A2 (fr) 2004-04-28
KR100996378B1 (ko) 2010-11-25
RU2004105961A (ru) 2005-03-20
IL159312A0 (en) 2004-06-01
EP1411918A4 (fr) 2007-11-14
KR20040020075A (ko) 2004-03-06
CY1112633T1 (el) 2015-08-05
NO2020003I1 (no) 2020-03-05
US20110129448A1 (en) 2011-06-02
SI2371361T1 (sl) 2019-10-30
PT1411918E (pt) 2012-03-06
NL301031I1 (nl) 2020-02-05
LU92033I9 (fr) 2019-01-03
DK1411918T3 (da) 2012-04-23
EP2371361A1 (fr) 2011-10-05
LU92033I2 (fr) 2012-08-27
BRPI0211570B1 (pt) 2020-01-28
US20130273009A1 (en) 2013-10-17
US7897590B2 (en) 2011-03-01
LTC2371361I2 (lt) 2021-09-27
HUP0402360A2 (hu) 2005-02-28
FR12C0042I1 (fr) 2012-08-10
NO20150674A1 (no) 2015-05-27
JP2008195730A (ja) 2008-08-28
CY2019038I2 (el) 2020-05-29
JP2004538303A (ja) 2004-12-24
CY2012017I2 (el) 2015-08-05
EP2371361B1 (fr) 2019-08-07
WO2003011277A2 (fr) 2003-02-13
CY2012017I1 (el) 2015-08-05
AU2002318927B2 (en) 2007-01-04
NO344632B1 (no) 2020-02-17
DK2371361T3 (da) 2019-08-19
CA2455559A1 (fr) 2003-02-13
SI1411918T1 (sl) 2012-04-30
WO2003011277A3 (fr) 2003-05-22

Similar Documents

Publication Publication Date Title
LUC00139I1 (fr)
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
WO1994019343A3 (fr) Nouvelle application des composes bis-heterocycliques et les compositions pharmaceutiques en tant qu'agents anti-inflammatoires
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
ATE46511T1 (de) Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
EP1142883A4 (fr) Nouveaux composes heterocycliques et compositions de medicaments les renfermant
OA09239A (fr) "Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (fr) Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EP1057829A4 (fr) Dérivés de la pyrimidine condensés et compositions pharmaceutiques les contenant
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции